Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)

Thierry Facon, MD, of Lille University Hospital, Lille, France, presents the interim results of the Phase III MAIA trial (NCT02252172). The trial looked at the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. lenalidomide/dexamethasone (Rd) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). Excitingly, the D-Rd regimen significantly reduced the risk of progression or death, with no new safety concerns. Dr Facon was speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.